# Tocilizumab for the Treatment of Refractory Behcet's Uveitis

> **NCT03554161** · PHASE2 · TERMINATED · sponsor: **Wenjie Zheng** · enrollment: 3 (actual)

## Conditions studied

- Behcet Syndrome
- Uveitis

## Interventions

- **BIOLOGICAL:** Tocilizumab (TCZ)

## Key facts

- **NCT ID:** NCT03554161
- **Lead sponsor:** Wenjie Zheng
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-10
- **Primary completion:** 2021-02-01
- **Final completion:** 2021-02-01
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** The study was terminated based on its primary and secondary outcome measures in three consecutive patients.
- **Last updated:** 2021-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03554161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03554161, "Tocilizumab for the Treatment of Refractory Behcet's Uveitis". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03554161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*